domain-B Researchers bound the most clinically-used growth factor, BMP-2, with microparticles of the drug heparin at concentrations up to 1,000-fold higher than previously reported. Credit: Todd McDevitt/Rhys Black. A new technology under development at the ...
24/7 Wall St. Additionally, low-molecular weight heparin will be used as a prophylaxis to prevent thromboembolic events. Again, Halozyme has seen its share of volatili...
Boston Business Journal (blog) The drug is a type of so-called heparin , a biologic molecule commonly used to prevent blood clotting but which also has the ability to f...
Medscape As previously reported by heartwire , the multicenter EUROMAX trial demonstrated that STEMI patients treated with bivalirudin had lower 30-day rates of death or...
Medical Xpress In a recent study, researchers bound the most clinically-used growth factor with microparticles of the drug heparin at concentrations up to 1,000-fold higher than previously reported. The growth factor, called bone morphogenetic protein-2 (BMP-2), also ... and more »
MarketWatch The Agreement marks a shift in the Company's strategy to accelerate sales of its two signature PIFA Heparin Tests to hospitals. The PIFA Heparin Tests ar...
HealthCanal.com Las Vegas, Nev. — Two new studies that compared the safety and effectiveness of heparin and bivalirudin in percutaneous coronary intervention (PCI) will add fuel to the recent debate about the relative merits of the two anticoagulation medications, ...
